MedPath
Found 5 clinical trials|View Analysis
Sort by:

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

Phase 2
Recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
First Posted Date
2023-03-09
Last Posted Date
2024-06-27
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
245
Registration Number
NCT05762536
Locations
🇳🇱

Erasmus MC Cancer Institute, Rotterdam, Netherlands

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Phase 1
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2017-02-06
Last Posted Date
2020-02-17
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
4
Registration Number
NCT03043989
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Phase 4
Terminated
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
First Posted Date
2015-05-12
Last Posted Date
2018-04-19
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
4
Registration Number
NCT02441517
Locations
🇺🇸

Site US10004, New York, New York, United States

🇺🇸

Site US10003, Evanston, Illinois, United States

🇺🇸

Site US10002, Myrtle Beach, South Carolina, United States

and more 2 locations

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

Conditions
Advanced Prostate Cancer
Cabazitaxel
Docetaxel
First Posted Date
2015-02-13
Last Posted Date
2020-01-27
Lead Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Target Recruit Count
402
Registration Number
NCT02362620
Locations
🇪🇸

Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

🇪🇸

ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain

🇪🇸

Hospital Althaia Manresa, Manresa, Barcelona, Spain

and more 22 locations

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 3
Terminated
Conditions
Hormone Refractory Prostate Cancer
Castrate-Resistant Prostate Cancer
Interventions
First Posted Date
2010-03-10
Last Posted Date
2016-10-12
Lead Sponsor
Achieve Life Sciences
Target Recruit Count
14
Registration Number
NCT01083615
© Copyright 2025. All Rights Reserved by MedPath